These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 33206579)

  • 1. Correlation between immunohistochemical expression of Ki-67and P63 and aggressiveness of urinary bladder urothelial carcinoma.
    Abdallah MM; Wahbbah MA; Selem M; Abdou AG; Sultan SM
    J Immunoassay Immunochem; 2021 Mar; 42(2):188-201. PubMed ID: 33206579
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ki-67 and Cell Cycle Regulators p53, p63 and cyclinD1 as Prognostic Markers for Recurrence/ Progression of Bladder Urothelial Carcinoma.
    El-Gendi S; Abu-Sheasha G
    Pathol Oncol Res; 2018 Apr; 24(2):309-322. PubMed ID: 28488128
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic value of Ki67 and p63 expressions in bladder cancer patients who underwent radical cystectomy.
    Wang L; Zhou M; Feng C; Gao P; Ding G; Zhou Z; Jiang H; Wu Z; Ding Q
    Int Urol Nephrol; 2016 Apr; 48(4):495-501. PubMed ID: 26759323
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of cell-cycle regulatory proteins and their prognostic value in superficial low-grade urothelial cell carcinoma of the bladder.
    Santos LL; Amaro T; Pereira SA; Lameiras CR; Lopes P; Bento MJ; Oliveira J; Criado B; Lopes CS
    Eur J Surg Oncol; 2003 Feb; 29(1):74-80. PubMed ID: 12559081
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of p53 and Ki-67 immunomarkers in carcinoma of urinary bladder.
    Thakur B; Kishore S; Dutta K; Kaushik S; Bhardwaj A
    Indian J Pathol Microbiol; 2017; 60(4):505-509. PubMed ID: 29323062
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low-level Ki-67 expression as an independent predictor of bladder tumour recurrence in patients with primary upper tract urothelial carcinoma after radical nephroureterectomy.
    Wu P; Liu S; Zhang W; Zhang Y; Zhu G; Wei D; Wan B; Wang J
    Jpn J Clin Oncol; 2015 Dec; 45(12):1175-81. PubMed ID: 26450700
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunohistochemical expression of p63, p53 in urinary bladder carcinoma.
    Koyuncuer A
    Indian J Pathol Microbiol; 2013; 56(1):10-5. PubMed ID: 23924551
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunohistochemical expression of p63, p53 and MIB-1 in urinary bladder carcinoma. A tissue microarray study of 158 cases.
    Compérat E; Camparo P; Haus R; Chartier-Kastler E; Bart S; Delcourt A; Houlgatte A; François R; Capron F; Vieillefond A
    Virchows Arch; 2006 Mar; 448(3):319-24. PubMed ID: 16283378
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination of CK20 and Ki-67 immunostaining analysis predicts recurrence, progression, and cancer-specific survival in pT1 urothelial bladder cancer.
    Bertz S; Otto W; Denzinger S; Wieland WF; Burger M; Stöhr R; Link S; Hofstädter F; Hartmann A
    Eur Urol; 2014 Jan; 65(1):218-26. PubMed ID: 22633802
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Immunohistochemical study of p53 and Ki-67 overexpression in grade 3 superficial bladder tumor in relationship to tumor recurrence and prognosis].
    Ikegami S; Yoshimura I; Tsuji A; Seta K; Kimura F; Odajima K; Asano T; Hayakawa M
    Nihon Hinyokika Gakkai Zasshi; 2001 Nov; 92(7):656-65. PubMed ID: 11766364
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cell-cycle control in urothelial carcinoma: large-scale tissue array analysis of tumor tissue from Maine and Vermont.
    Lenz P; Pfeiffer R; Baris D; Schned AR; Takikita M; Poscablo MC; Schwenn M; Johnson A; Jones M; Kida M; Cantor KP; Rothman N; Silverman DT; Hewitt SM; Moore LE
    Cancer Epidemiol Biomarkers Prev; 2012 Sep; 21(9):1555-64. PubMed ID: 22761304
    [TBL] [Abstract][Full Text] [Related]  

  • 12. p16 INK4a overexpression and p16/Ki-67 dual labeling versus conventional urinary cytology in the evaluation of urothelial carcinoma.
    Piaton E; Carré C; Advenier AS; Decaussin-Petrucci M; Mège-Lechevallier F; Lantier P; Granier G; Ruffion A
    Cancer Cytopathol; 2014 Mar; 122(3):211-20. PubMed ID: 24302621
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fascin is a predictor for invasiveness and recurrence of urothelial carcinoma of bladder.
    Bi J; Chen X; Zhang Y; Li B; Sun J; Shen H; Kong C
    Urol Oncol; 2012 Sep; 30(5):688-94. PubMed ID: 20888270
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ki-67 index enhances the prognostic accuracy of the urothelial superficial bladder carcinoma risk group classification.
    Santos L; Amaro T; Costa C; Pereira S; Bento MJ; Lopes P; Oliveira J; Criado B; Lopes C
    Int J Cancer; 2003 Jun; 105(2):267-72. PubMed ID: 12673690
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proliferative status is a risk index for recurrence in primary superficial (pTa/T1) low-grade urothelial bladder carcinoma.
    Su JS; Arima K; Hasegawa M; Franco OE; Yanagawa M; Sugimura Y; Kawamura J
    Hinyokika Kiyo; 2003 Nov; 49(11):649-58. PubMed ID: 14719452
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inverse p16 and p63 expression in small cell carcinoma and high-grade urothelial cell carcinoma of the urinary bladder.
    Buza N; Cohen PJ; Pei Hui ; Parkash V
    Int J Surg Pathol; 2010 Apr; 18(2):94-102. PubMed ID: 20164052
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic significance of p53, bcl-2 and Ki-67 in high risk superficial bladder cancer.
    Stavropoulos NE; Filiadis I; Ioachim E; Hastazeris K; Tsimaris I; Kalogeras D; Stefanaki S; Agnantis NJ
    Anticancer Res; 2002; 22(6B):3759-64. PubMed ID: 12552989
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quantitative molecular grading of bladder tumours: a tool for objective assessment of the biological potential of urothelial neoplasias.
    Bollmann D; Bollmann M; Bankfalvi A; Heller H; Bollmann R; Pajor G; Hildenbrand R
    Oncol Rep; 2009 Jan; 21(1):39-47. PubMed ID: 19082441
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ki67 and Bcl-2 immunoexpression in primitive urothelial bladder carcinoma.
    Enache M; Simionescu C; Lascu LC
    Rom J Morphol Embryol; 2012; 53(3):521-5. PubMed ID: 22990542
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Introduction and first clinical application of a simplified immunohistochemical validation system confirms prognostic impact of KI-67 and CK20 for stage T1 urothelial bladder carcinoma: single-center analysis of eight biomarkers in a series of three hundred six patients.
    Otto W; Denzinger S; Fritsche HM; Burger M; Rößler W; Bertz S; May M; Hartmann A; Hofstädter F; Wieland WF; Eder F
    Clin Genitourin Cancer; 2013 Dec; 11(4):537-44. PubMed ID: 23850551
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.